Category: FXN Companies

The gene therapy[1] startup AavantiBio[2] has launched with $107 million in funding to advance its lead clinical program for the treatment of Friedreich’s ataxia[3] (FA). Early this year, the Boston-based company received[4] a $1 million grant from the Muscular Dystrophy Association[5] (MDA)’s Venture Philanthropy Fund[6] to start producing its gene therapy candidate, expected to be tested in a Phase 2 clinical...

LONDON–(BUSINESS WIRE)–Jul 26, 2018–Technavio has announced their latest pipeline analysis report on the . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat Friedreich’s ataxia.[1] This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180726005803/en/[2] Technavio has published a new report on the drug development pipeline for Friedreich’s...

Please do not submit Protected Health Information (PHI) through this email address. If you need to submit Protected Health Information (PHI), please call us at 617-209-2090 and we will work with you to submit the information through an alternate mechanism. Otherwise, please continue: Read Article to Me (Mobile Version)